In another blow to MSCs developer, Pluristem terminates a failed lead program
A tough year for mesenchymal stem cell companies just got tougher.
Pluristem, the NASA-allied Israeli stem cell biotech, announced Monday that a data monitoring committee …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.